Previous 10 | Next 10 |
The following slide deck was published by Assertio Therapeutics, Inc. in conjunction with this Read more ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
LAKE FOREST, Ill., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31 st Annual Piper Jaffray Healthcare Conference in a session scheduled for 9:30 a.m. ET, Thursday, December 5, 2019 in ...
Company Thesis Assertio Therapeutics ( ASRT ) is a specialty pharmaceuticals company which successfully divested itself of its painkiller exposure in response to the opioid crisis. Unfortunately, the company has zero growth catalysts within the next 3-5 years due to lack of scientific data...
LAKE FOREST, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Stifel Healthcare Conference in a session scheduled for 10:20 a.m. ET, Wednesday, November 20, 2019 in New York, NY....
Assertio Therapeutics, Inc. (ASRT) Q3 2019 Earnings Conference Call November 06, 2019 4:30 PM ET Company Participants John Thomas - Senior Vice President, Investor Relations & Corporate Communications Arthur Higgins - President & Chief Executive Officer Dan Peisert - Seni...
The following slide deck was published by Assertio Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Assertio Therapeutics (NASDAQ: ASRT ): Q3 Non-GAAP EPS of $0.24 in-line; GAAP EPS of $0.05 beats by $0.26 . Revenue of $55.1M (-28.9% Y/Y) misses by $5.64M . Press Release More news on: Assertio Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- Company Implements New Cost Savings Initiatives Expected to Deliver Annualized Savings of $20.0 Million -- -- Raises Full-Year 2019 Earnings Guidance Ranges -- -- Lowers Full-Year 2019 Neurology Franchise Net Sales Guidance -- -- Reduces Total Debt by $200.0 Million Year t...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...